DE60115569D1 - Phenoxazinanaloge zur Behandlung von Amyloidose - Google Patents

Phenoxazinanaloge zur Behandlung von Amyloidose

Info

Publication number
DE60115569D1
DE60115569D1 DE60115569T DE60115569T DE60115569D1 DE 60115569 D1 DE60115569 D1 DE 60115569D1 DE 60115569 T DE60115569 T DE 60115569T DE 60115569 T DE60115569 T DE 60115569T DE 60115569 D1 DE60115569 D1 DE 60115569D1
Authority
DE
Germany
Prior art keywords
hydrogen
lower alkyl
phenoxazine
amyloidosis
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60115569T
Other languages
English (en)
Other versions
DE60115569T2 (de
Inventor
Corinne Elizab Augelli-Szafran
Yingije Lai
Tomoyuki Yasunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE60115569D1 publication Critical patent/DE60115569D1/de
Application granted granted Critical
Publication of DE60115569T2 publication Critical patent/DE60115569T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60115569T 2000-09-29 2001-09-21 Phenoxazinanaloge zur Behandlung von Amyloidose Expired - Fee Related DE60115569T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23696600P 2000-09-29 2000-09-29
US236966P 2000-09-29

Publications (2)

Publication Number Publication Date
DE60115569D1 true DE60115569D1 (de) 2006-01-12
DE60115569T2 DE60115569T2 (de) 2006-08-10

Family

ID=22891762

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60115569T Expired - Fee Related DE60115569T2 (de) 2000-09-29 2001-09-21 Phenoxazinanaloge zur Behandlung von Amyloidose

Country Status (10)

Country Link
US (1) US20020143012A1 (de)
EP (1) EP1193260B1 (de)
JP (1) JP2002201186A (de)
AT (1) ATE312086T1 (de)
BR (1) BR0104344A (de)
CA (1) CA2357450A1 (de)
DE (1) DE60115569T2 (de)
DK (1) DK1193260T3 (de)
ES (1) ES2253315T3 (de)
MX (1) MXPA01009768A (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656141B1 (de) * 2003-08-07 2010-04-14 MERCK SHARP & DOHME LTD. Behandlung von alzheimer-krankheit und verwandten zuständen
DE602004004280T2 (de) * 2003-08-18 2007-06-21 Novartis Ag Als mittel zur nahinfrarotabbildung geeignete 3h-phenoxazinderivate, deren herstellung und verwendung
GB0410238D0 (en) 2004-05-07 2004-06-09 Merck Sharp & Dohme Therapeutic agents
CA2668744C (en) * 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2014032732A1 (de) * 2012-08-28 2014-03-06 Eberhard Karls Universität Tübingen Medizinische Fakultät Halogenierte benzoxazine und ihre verwendung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
HUP0201586A2 (en) * 1999-06-10 2002-08-28 Warner Lambert Co Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
AP2002002387A0 (en) * 1999-06-10 2002-03-31 Warner Lambert Co Method of inhibiting amyloid aggregation and imaging amyloid deposits.

Also Published As

Publication number Publication date
JP2002201186A (ja) 2002-07-16
EP1193260A1 (de) 2002-04-03
MXPA01009768A (es) 2004-08-12
DE60115569T2 (de) 2006-08-10
CA2357450A1 (en) 2002-03-29
ATE312086T1 (de) 2005-12-15
DK1193260T3 (da) 2006-04-10
US20020143012A1 (en) 2002-10-03
EP1193260B1 (de) 2005-12-07
ES2253315T3 (es) 2006-06-01
BR0104344A (pt) 2003-03-05

Similar Documents

Publication Publication Date Title
RU95105423A (ru) Гетероциклические соединения, обладающие антидиабетической активностью
EA200200976A1 (ru) Способ лечения или ингибирования полипов ободочной кишки
NO20045369L (no) Nye, substituerte sulfamatanticonvulsivaderivater
ATE478872T1 (de) Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
EA200200661A1 (ru) 3-аминохиназолин-2,4-дионовые антибактериальные агенты
GB0318343D0 (en) No title
NO20023456D0 (no) Nitrogenholdige forbindelser og farmasöytiske preparater inneholdende de samme
DK0959906T3 (da) Delta 1,6 bicyclo[4,4,0] funktionelle farver til kontrastforøgelse ved optisk afbildning
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
DE69824025D1 (de) 6,7-asymmetrisch disubstituierte chinoxalincarbonsäurederivate, additionssalze davon und verfahren zur herstellung von beiden
AU2001255646A1 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
DE69423459D1 (de) Dihydrat des N-(4-Amino-6,7-dimethoxychinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylendiamin Hydrochlorids(=Alfuzosin Hydrochlorid Dihydrat) und ein Verfahren zur Herstellung
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
DE60115569D1 (de) Phenoxazinanaloge zur Behandlung von Amyloidose
ATE209184T1 (de) In 6-s und/oder 8-s durch 3- methylthiopropanoylrest substituierte 6,8- dimethylmercaptooctansäure-derivate und pharmaceutische zubereitungen zur behandlung von krebstumoren
ATE277887T1 (de) Verfahren zur herstellung von 1,4-bis((2- (dimethylamino)ethyl amino)-5,8- dihydroxyanthracene-9,10-dion
CA2285535A1 (en) Benzimidazole derivative for treating allergy-related disease
DE59604901D1 (de) Carbamoylcarbonsäureamide
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
RU2365594C2 (ru) Применение циклических пептидов анабенопептинового типа для лечения состояния, при котором полезно ингибирование карбоксипептидазы u, новые анабенопептиновые производные и их промежуточные соединения
HUP0000966A2 (hu) Izoflavonszármazékok és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények
WO2004035002A3 (en) Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
ATE31059T1 (de) N-(arylpropyl)-azolylharnstoffe und diese enthaltende fungizide.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee